Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Politicization and misinformation or disinformation of unproven COVID-19 therapies have resulted in communication challenges in presenting science to the public, especially in times of heightened public trepidation and uncertainty.
Objective: This study aims to examine how scientific evidence and uncertainty were portrayed in US news on 3 unproven COVID-19 therapeutics, prior to the development of proven therapeutics and vaccines.
Methods: We conducted a media analysis of unproven COVID-19 therapeutics in early 2020. A total of 479 discussions of unproven COVID-19 therapeutics (hydroxychloroquine, remdesivir, and convalescent plasma) in traditional and online US news reports from January 1, 2020, to July 30, 2020, were systematically analyzed for theme, scientific evidence, evidence details and limitations, safety, efficacy, and sources of authority.
Results: The majority of discussions included scientific evidence (n=322, 67%) although only 24% (n=116) of them mentioned publications. "Government" was the most frequently named source of authority for safety and efficacy claims on remdesivir (n=43, 35%) while "expert" claims were mostly mentioned for convalescent plasma (n=22, 38%). Most claims on hydroxychloroquine (n=236, 79%) were offered by a "prominent person," of which 97% (n=230) were from former US President Trump. Despite the inclusion of scientific evidence, many claims of the safety and efficacy were made by nonexperts. Few news reports expressed scientific uncertainty in discussions of unproven COVID-19 therapeutics as limitations of evidence were infrequently included in the body of news reports (n=125, 26%) and rarely found in headlines (n=2, 2%) or lead paragraphs (n=9, 9%; P<.001).
Conclusions: These results highlight that while scientific evidence is discussed relatively frequently in news reports, scientific uncertainty is infrequently reported and rarely found in prominent headlines and lead paragraphs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393509 | PMC |
| http://dx.doi.org/10.2196/51328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A cluster randomised feasibility trial assessing an interactive film intervention to improve wellbeing of young people in school settings in the North of England.
Pilot Feasibility Stud
September 2025
School of Sport and Physical Activity, Sheffield Hallam University, Sheffield, UK.
Background: Adolescence is a critical period for the onset of mental illness. A partnership of a health and care network and filmmakers developed an interactive film for youth wellbeing. While such films have potential as a cost-effective preventative tool, their effectiveness remains unproven.
View Article and Find Full Text PDFRetinal Vascular Occlusion Following COVID-19 Vaccination: A Comprehensive Review of Observational Study and Pathophysiological Mechanisms.
Vaccines (Basel)
July 2025
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
: Retinal vascular occlusion (RVO) and retinal artery occlusion (RAO) have been reported as rare adverse events following COVID-19 vaccination, raising concerns about vaccine safety. This review synthesizes cohort and case-control studies assessing the association between COVID-19 vaccines and RVO/RAO, while exploring potential pathophysiological mechanisms. : We analyzed large-scale population-based studies from South Korea, Europe, and the TriNetX database, focusing on odds ratios (OR), hazard ratios (HR), and relative risks (RR) across mRNA and adenoviral vector vaccines.
View Article and Find Full Text PDFSelf-medication and off-label prescribing in post COVID-19 syndrome: Baseline data of a randomized acupressure and qigong trial.
Integr Med Res
September 2025
Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background: Post COVID-19 syndrome (PCS), characterized by persistent fatigue and multi-systemic symptoms following SARS-CoV-2 infection, emerged as a clinical challenge with limited treatment options and high patient burden. This paper presents the medication history and clinical baseline characteristics of PCS patients recruited in a randomized controlled trial (RCT).
Methods: Patients who reported PCS symptoms of ≥12 weeks after SARS-CoV-2 infection and who met defined fatigue criteria were included in this study.
Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID-19 Infection: Two Case Reports With Literature Review.
Respirol Case Rep
July 2025
Division of Pulmonary and Critical Care Medicine West Virginia University School of Medicine, and Institute for Academic Medicine/Vandalia Health Charleston West Virginia USA.
Anti-CD20 medications, such as rituximab and coronavirus disease 2019 (COVID-19) infection, have been shown to cause secondary organising pneumonia (OP). Ocrelizumab is an anti-CD20 monoclonal antibody widely used as a disease-modifying therapy for relapsing-remitting and primary progressive forms of multiple sclerosis (MS). We describe two cases of biopsy-proven secondary OP in ocrelizumab-treated MS patients occurring several weeks after contracting COVID-19 infection.
View Article and Find Full Text PDFA case of IgG4-related disease potentially triggered by COVID-19 vaccination: longitudinal serum IgG4 monitoring from prevaccination.
Mod Rheumatol Case Rep
July 2025
Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
We report a case of a 64-year-old Japanese man who developed IgG4-related pericoronary arteritis following mRNA-based COVID-19 vaccination. The patient presented with anterior chest pain and imaging revealed perivascular soft tissue thickening around the coronary arteries, along with pancreatic enlargement, enlarged prostate, and periaortitis. Laboratory tests showed markedly elevated serum IgG4 levels (1740 mg/dl).
View Article and Find Full Text PDF